# Celcuity

Source: https://onco.cc/companies/celcuity/  
OnCo record `celcuity` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Celcuity developed gedatolisib, approved in July 2026 for hormone-positive breast cancer.

## Summary

Celcuity, based in Minneapolis and listed as CELC, developed gedatolisib, a pan-PI3K and mTOR inhibitor approved in July 2026 for hormone-receptor-positive breast cancer. Gedatolisib, sold as Revtorpyk, is given with palbociclib and fulvestrant, and the VIKTORIA-1 and VIKTORIA-2 trials are the evidence behind it. OnCo links it to HR-positive, HER2-negative breast cancer and to the gedatolisib drug record. Whether a pan-PI3K and mTOR inhibitor can be tolerated well enough in routine practice to displace mutation-selective PI3K drugs is the open question. Gedatolisib has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Minneapolis, MN
- Type: biotech
- Website: https://www.celcuity.com
- Ticker: CELC

## Sources

- Official website: https://www.celcuity.com

## Connected records

- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Gedatolisib](https://onco.cc/drugs/gedatolisib/), [Serabelisib](https://onco.cc/drugs/serabelisib/)
- trials: [Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer](https://onco.cc/trials/nct06190899/), [Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)](https://onco.cc/trials/nct05501886/), [Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)](https://onco.cc/trials/nct06757634/)
- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)

---
JSON: https://onco.cc/api/v1/entities/celcuity.json